Literature DB >> 11605169

Pathophysiology of alpha- and beta-thalassemia: therapeutic implications.

D Rund1, E Rachmilewitz.   

Abstract

At the molecular level, the underlying cause of thalassemia is any of a number of genetic lesions that reduce or abolish the production of the globin chains of hemoglobin. The resulting chain imbalance is the key factor initiating the damage to the red blood cell (RBC) and it is the major pathophysiological event in all forms of the thalassemia syndromes. In this review we will outline some of the cellular and systemic processes that have been implicated in the development of the disease. When relevant, we will discuss the ways in which these processes can be altered in a therapeutic manner. Copyright 2001 by W.B. Saunders Company.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11605169     DOI: 10.1016/s0037-1963(01)90028-9

Source DB:  PubMed          Journal:  Semin Hematol        ISSN: 0037-1963            Impact factor:   3.851


  8 in total

1.  A 191-kb genomic fragment containing the human alpha-globin locus can rescue alpha-thalassemic mice.

Authors:  Keith Al-Hasani; Jim Vadolas; Anja S Knaupp; Hady Wardan; Lucille Voullaire; Robert Williamson; Panayiotis A Ioannou
Journal:  Mamm Genome       Date:  2005-11-11       Impact factor: 2.957

2.  Evaluation of new cases of HCV infection in thalassaemia patients for source of infection.

Authors:  Azita Azarkeivan; Mohsen Nasiritoosi; Sedigheh Amini Kafiabad; Mahtab Maghsudlu; Bashir Hajibeigi; Mohammad Hadizadeh
Journal:  Asian J Transfus Sci       Date:  2011-07

3.  A combined approach for β-thalassemia based on gene therapy-mediated adult hemoglobin (HbA) production and fetal hemoglobin (HbF) induction.

Authors:  Cristina Zuccato; Laura Breda; Francesca Salvatori; Giulia Breveglieri; Sara Gardenghi; Nicoletta Bianchi; Eleonora Brognara; Ilaria Lampronti; Monica Borgatti; Stefano Rivella; Roberto Gambari
Journal:  Ann Hematol       Date:  2012-03-31       Impact factor: 3.673

4.  Watershed Infarct in Beta-Thalassemia Major Patient.

Authors:  Behnaz Ansari; Mohammad Saadatnia; Ali Asghar Okhovat
Journal:  Case Rep Neurol Med       Date:  2017-03-27

5.  Protection against oxidative stress in beta thalassemia/hemoglobin E erythrocytes by inhibitors of glutathione efflux transporters.

Authors:  Chatchai Muanprasat; Chokdee Wongborisuth; Nutthapoom Pathomthongtaweechai; Saravut Satitsri; Suradej Hongeng
Journal:  PLoS One       Date:  2013-01-31       Impact factor: 3.240

6.  Generation and Characterization of a Transgenic Mouse Carrying a Functional Human β -Globin Gene with the IVSI-6 Thalassemia Mutation.

Authors:  Giulia Breveglieri; Irene Mancini; Nicoletta Bianchi; Ilaria Lampronti; Francesca Salvatori; Enrica Fabbri; Cristina Zuccato; Lucia C Cosenza; Giulia Montagner; Monica Borgatti; Fiorella Altruda; Sharmila Fagoonee; Gianni Carandina; Michele Rubini; Vincenzo Aiello; Laura Breda; Stefano Rivella; Roberto Gambari; Alessia Finotti
Journal:  Biomed Res Int       Date:  2015-05-04       Impact factor: 3.411

7.  Retinal nerve fiber layer thickness and retinal vessel calibers in children with thalassemia minor.

Authors:  Semra Acer; Yasemin I Balcı; Gökhan Pekel; Tuğba T Ongun; Aziz Polat; Ebru N Çetin; Ramazan Yağcı
Journal:  SAGE Open Med       Date:  2016-08-02

8.  Retinal and Choriocapillaris Vascular Changes in Patients Affected by Different Clinical Phenotypes of β-Thalassemia: An Optical Coherence Tomography Angiography Study.

Authors:  Gilda Cennamo; Daniela Montorio; Giuliano Mazzella; Paolo Ricchi; Silvia Costantini; Anna Spasiano; Aldo Filosa; Maria Rosaria Storino; Francesca Aquila; Fausto Tranfa; Michela Grosso
Journal:  Biology (Basel)       Date:  2021-03-28
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.